R&D Pipeline

Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.

Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.

NKTR-181

Indication: Treatment of moderate to severe chronic low back pain

Discovered and wholly owned by Nektar

Unpartnered

NDA Filed

ONZEALD (etirinotecan pegol)

Indication: Advanced breast cancer and brain metastases

Discovered and wholly owned by Nektar

Unpartnered

Phase 3

NKTR-214 in combination with OPDIVO® (nivolumab)

Indication: Renal Cell Carcinoma

Partner
Partner

Phase 3

PEGPH20

Indication: Pancreatic cancer

Partner
Partner

Phase 3

PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan (HA). Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is an indicator of poor prognosis. PEGPH20 has been shown to deplete this matrix component from the tumor that rapidly changes the tumor microenvironment and metabolism, which may render the tumor more vulnerable to therapy as well as inhibit tumor growth. PEGPH20 is being evaluated in a Phase 3 HALO 301 study as a first-line therapy for patients with metastatic pancreatic cancer. The trial will be conducted at approximately 200 sites with two co-primary endpoints of progression free survival and overall survival in patients receiving investigational new drug PEGPH20 in combination with gemcitabine and ABRAXANE (nab-paclitaxel) compared to gemcitabine and nab-paclitaxel alone. Additional clinical studies for PEGPH20 include a Phase 1b clinical study evaluating PEGPH20 in combination with KEYTRUDA® (pembrolizumab) in relapsed lung and gastric cancer patients; and a Phase 1b/2 clinical collaboration with Eisai evaluating eribulin in combination with PEGPH20 in women with advanced or metastatic, HER2-negative, HA-high breast cancer.

Nektar has an exclusive worldwide license agreement with Halozyme for PEGPH20. As part of the agreement, Nektar is entitled to development and commercial milestones and royalties on product sales of PEGPH20.

NKTR-214 in combination with OPDIVO® (nivolumab)

Research Focus: Immuno-oncology

Discovered by Nektar

In clinical collaboration with Collaborator

Phase 2

Dapirolizumab Pegol (Anti-CD40L)

Indication: Systemic lupus erythematosus (SLE)

Partner
Partner

In partnership with Partner

Phase 2

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that occurs when the body's own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (Anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in SLE patients. Dapirolizumab pegol is being developed by Biogen and UCB, Inc. in a Phase 2 clinical trial to evaluate the efficacy and safety of dapirolizumab pegol in patients with moderately to severely active systemic lupus erythematosus. For more information about this study, visit clinicaltrials.gov.

NKTR-214 in combination with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab)

Research Focus: Immuno-oncology

Discovered and wholly owned by Nektar

Unpartnered

Phase 1

NKTR-358

RESEARCH FOCUS: Autoimmune Disease

Discovered by Nektar

Partner
Partner

Phase 1

NKTR-262 in combination with NKTR-214

RESEARCH FOCUS: Immuno-oncology

Discovered and wholly owned by Nektar

Unpartnered

Phase 1

NKTR-214 in combination with TAK-659

Research Focus: Non-Hodgkin Lymphoma

Discovered by Nektar

In clinical collaboration with Collaborator

Phase 1

NKTR-255

RESEARCH FOCUS: Immuno-oncology

Discovered and wholly owned by Nektar

Unpartnered

Preclinical

NKTR-255 is a memory T cell stimulating cytokine designed to engage the IL-15 pathway to enhance and sustain long-term T cell memory response to treat cancer.


ONZEALD is a trademark of Nektar Therapeutics; ADYNOVI is a trademark of Baxalta Incorporated, a wholly owned subsidiary of Shire plc; OPDIVO® is a registered trademark of Bristol-Myers Squibb; TECENTRIQ is a registered trademark of Genentech, Inc.